Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiviral Therapy to Prevent Mother-to-Infant HBV Transmission
NCT03695029Phase 4Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Dec 2010
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir alafenamide in hepatitis B (HBV) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Child Hepatitis B Surface Antigen at 6 months. Status: unknown.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03695029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03695029.